Feb 20 (Reuters) - Cyclopharm Ltd CYC.AX :
* RESOLVED TO PAY FINAL UNFRANKED DIVIDEND OF 0.5 AU CENTS
PER
SHARE
* FY PRELIMINARY REVENUES FROM ORDINARY ACTIVITIES UP 31.1%
TO
A$23.2 MILLION
* REMAINS CONFIDENT THAT EXPECTATIONS OF TRIAL RESULTS BEING
PUBLISHED IN FIRST HALF OF 2023 WILL BE MET
* FY LOSS FOR THE YEAR A$6.6 MILLION VERSUS LOSS A$5.0
MILLION
* CONTINUES TO PROGRESS TOWARD ATTAINING USFDA APPROVAL TO
COMMENCE COMMERCIAL SALES OF TECHNEGAS IN US MARKET IN 2023
* POISED TO ENTER ITS NEXT GROWTH PHASE IN 2023
Source text for Eikon: ID:nASX3mBFqM
Further company coverage: CYC.AX
((Reuters.Briefs@thomsonreuters.com;))